ReviewTranslational research : the journal of laboratory and clinical medicine2020
Fibrinolytics for the treatment of pulmonary embolism.
Review in Translational research : the journal of laboratory and clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Tenecteplase in Pulmonary Embolism Patients: A Meta-Analysis and Systematic Review.Frontiers in medicine · 2022Pooled it
- Thrombolytic therapy for pulmonary embolism.The Cochrane database of systematic reviews · 2021Pooled it
- Real-world analysis of fibrinolytics-associated bleeding and literature synthesis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Personalised viscoelastometry-guided systemic thrombolysis for high- and intermediate-high-risk acute pulmonary embolism in the ICU: a single-centre randomised controlled interventional feasibility trial.Intensive care medicine experimental · 2026Article
- Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Review
- Velefibrinase: A Marine-Derived Fibrinolytic Enzyme with Multi-Target Antithrombotic Effects Across Diverse In Vivo Models.Biomedicines · 2025Article
- From bench to bedside: the role of tailoring fibrinolysis in pulmonary embolism.Journal of thrombosis and haemostasis : JTH · 2025Article
- Anticoagulation Management: Current Landscape and Future Trends.Journal of clinical medicine · 2025Review
- Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Menstruation-Related Angina-The Wee Hours.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment.Biomedicines · 2024Review
- Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis.BMC cardiovascular disorders · 2024Article
- Management of high-risk pulmonary embolism in the emergency department: A narrative review.The American journal of emergency medicine · 2024Review
- Evolving paradigm of thrombolysis in pulmonary embolism: Comprehensive review of clinical manifestations, indications, recent advances and guideline.World journal of clinical cases · 2023Review
- Breaking the fibrinolytic speed limit with microwheel co-delivery of tissue plasminogen activator and plasminogen.Journal of thrombosis and haemostasis : JTH · 2022Article
- Successful removal of a Life-threatening PE using the INARI flow triever device.Radiology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The use of fibrinolytic agents in acute pulmonary embolism (PE), first described over 50 years ago, hastens the resolution of RV stain, leading to earlier hemodynamic improvement. However, this benefit comes at the increased risk of bleeding. The strongest indication for fibrinolysis is in high-risk PE, or that characterized by sustained hypotension, while its use in patients with intermediate-risk PE remains controversial. Fibrinolysis is generally not recommended for routine use in intermediate-risk PE, although most guidelines advise that it may be considered in patients with signs of acute decompensation and an overall low bleeding risk. The efficacy of fibrinolysis often varies significantly between patients, which may be at least partially explained by several factors found to promote resistance to fibrinolysis. Ultimately, treatment decisions should carefully weigh the risks and benefits of the individual clinical scenario at hand, including the overall severity, the patient's bleeding risk, and the presence of factors known to promote resistance to fibrinolysis. This review aims to further explore the use of fibrinolytic agents in the treatment of PE including specific indications, outcomes, and special considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.